Woori Bank Co., Ltd. (WF) Forms $44.00 Double Bottom; Bellicum Pharmaceuticals, Inc. (BLCM) Had 9 Bullish Analysts

Among 11 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. Bellicum Pharmaceuticals Inc had 21 analyst reports since July 24, 2015 according to SRatingsIntel. The company was initiated on Thursday, February 25 by Citigroup. The company was downgraded on Wednesday, August 19 by Zacks. The rating was initiated by Citigroup with “Buy” on Friday, July 24. The rating was upgraded by Guggenheim on Friday, September 11 to “Buy”. Cantor Fitzgerald initiated the shares of BLCM in report on Wednesday, November 2 with “Buy” rating. On Tuesday, August 9 the stock rating was maintained by Citigroup with “Neutral”. The rating was maintained by Raymond James with “Outperform” on Wednesday, August 9. As per Monday, September 21, the company rating was downgraded by Zacks. Raymond James initiated the shares of BLCM in report on Thursday, December 1 with “Outperform” rating. The stock has “Buy” rating by Suntrust Robinson on Friday, June 3. See Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) latest ratings:

16/02/2018 Broker: Citigroup Rating: Buy New Target: $27.0
31/01/2018 Broker: SunTrust Rating: Buy New Target: $18.0
31/01/2018 Broker: Wells Fargo Rating: Hold New Target: $6.0 Downgrade

Woori Bank Co., Ltd. (WF) formed double bottom with $40.92 target or 7.00% below today’s $44.00 share price. Woori Bank Co., Ltd. (WF) has $9.88 billion valuation. The stock decreased 0.45% or $0.2 during the last trading session, reaching $44. About 104 shares traded. Woori Bank Co., Ltd. (NYSE:WF) has risen 62.14% since March 19, 2017 and is uptrending. It has outperformed by 45.44% the S&P500.

The stock decreased 2.39% or $0.19 during the last trading session, reaching $7.77. About 252,628 shares traded. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has risen 32.63% since March 19, 2017 and is uptrending. It has outperformed by 15.93% the S&P500.

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company has market cap of $260.85 million. The Company’s clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. It currently has negative earnings. The companyÂ’s preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma.